Page 6 - Demo
P. 6
⚫
Compared with other BC subtypes, patients with TNBC have:
TNBC is a potential target for immunotherapy based on immunogenicity
45
36
19
29
41
30
44
37
19
56
32
13
A higher mutation rate (large differences in mutations and biology even within tumours)1-3
Higher rate of T-cell infiltration4-6
Higher PD-L1 expression7-9
TNBC
ER+
All
TNBC
HER2+
Lum/HER2–
0% 20% 40% 60% 80% 100%
% of tumors
Low
(0–10% TILs)
Intermediate (11–59% TILs)
High (≥60% TILs)
12 10 8 6 4
1.Wang, et al. Nature 2014;
2. Stephens, et al. Nature 2009; 3. Banerji, et al. Nature 2012;
4. Lehmann, et al. J Clin Invest 2011;
5. Cimino-Matthews, et al. Hum Pathol 2013; 6. Loi, et al. Ann Oncol 2014;
7. Chen and Mellman. Immunity 2013;
8. Mittendorf, et al. Cancer Immunol Res 2014; 9. Nanda et al. J Clin Oncol 2016
Non-
TNBC TNBC
Mean ± SD of PD-L1 mRNA expression
